PTC announced promising 12 month results from their Phase 2 PIVOT-HD study of oral PTC518 – European Huntington Association

PTC today announced promising 12 month results from their Phase 2 PIVOT-HD study of oral PTC518.  

At Month 12, mutant Huntingtin (mHTT) in the blood was lowered by 22% and 43% respectively for 5mg and 10mg doses. A similar result was seen in cerebrospinal fluid, where mHTT was lowered by 21% and 43% respectively, for 5mg and 10mg doses.